At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.
Angiotech is Redefining Success
- Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (NASDAQ: ANPI, TSX: ANP). Read More...
If you are a Healthcare Professional and would like to learn more about Angiotech's products, please visit AngioEduPRO.com; Angiotech's Educational Resource for Healthcare Professionals.
Press Releases
- October 10 - Angiotech’s Corporate Partner, Boston Scientific, Announces FDA Approval of Second-Generation TAXUS® Liberté® Drug-Eluting Stent Read More...
- October 8 - Angiotech's Corporate Partner, Boston Scientific, Announces Completion of Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent Read More...
- All Press Releases
Highlights
- Angiotech will hold its Annual and Special General Meeting of Shareholders on October 30th Read More...
- Angiotech hosted a conference call discussing Second Quarter Financial Results on July 28th Read More...
